In an attempt to further improve the efficacy of immunotherapy in R/M HNSCC, combinations of PD-(L)1 inhibitors with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors were tested. Here, CTLA4 is linked to head and neck squamous cell carcinoma.